DDInter1666 DDInter474
In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently facilitates relief in pulmonary arterial hypertension and the increased flow of blood into the spongy erectile tissue of the penis that consequently allows it to grow in size and become erect and rigid [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Interestingly enough, it is precisely via this mechanism why sildenafil was at first researched as a potential treatment
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosuria. Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents. Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise. It was later approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease in April 2021.
Sildenafil {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Dapagliflozin
Sildenafil {u} (Compound) causes {v} (Side Effect) Hypoglycaemia
Hypoglycaemia {u} (Side Effect) is caused by {v} (Compound) Dapagliflozin
Sildenafil {u} (Compound) resembles {v} (Compound) Vardenafil
Vardenafil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapagliflozin
Sildenafil {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Progesterone
Progesterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapagliflozin
Sildenafil {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Canagliflozin
Canagliflozin {u} (Compound) resembles {v} (Compound) Dapagliflozin
Sildenafil {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Simvastatin
Simvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dapagliflozin
Sildenafil {u} (Compound) causes {v} (Side Effect) Hypoglycaemia
Hypoglycaemia {u} (Side Effect) is caused by {v} (Compound) Canagliflozin
Canagliflozin {u} (Compound) resembles {v} (Compound) Dapagliflozin
Sildenafil {u} (Compound) causes {v} (Side Effect) Fluid overload
Fluid overload {u} (Side Effect) is caused by {v} (Compound) Guanabenz
Guanabenz {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapagliflozin
Sildenafil {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Simvastatin
Simvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dapagliflozin
Sildenafil {u} (Compound) causes {v} (Side Effect) Acute coronary syndrome
Acute coronary syndrome {u} (Side Effect) is caused by {v} (Compound) Regorafenib
Regorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dapagliflozin
Sildenafil (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Dapagliflozin (Compound)
Sildenafil (Compound) causes Hypoglycaemia (Side Effect) and Hypoglycaemia (Side Effect) is caused by Dapagliflozin (Compound)
Sildenafil (Compound) resembles Vardenafil (Compound) and Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Sildenafil (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Progesterone (Compound) and Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Sildenafil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Canagliflozin (Compound) and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Sildenafil (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Simvastatin (Compound) and Simvastatin may cause a minor interaction that can limit clinical effects when taken with Dapagliflozin
Sildenafil (Compound) causes Hypoglycaemia (Side Effect) and Hypoglycaemia (Side Effect) is caused by Canagliflozin (Compound) and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Sildenafil (Compound) causes Fluid overload (Side Effect) and Fluid overload (Side Effect) is caused by Guanabenz (Compound) and Guanabenz may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Sildenafil (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Simvastatin (Compound) and Simvastatin may cause a minor interaction that can limit clinical effects when taken with Dapagliflozin
Sildenafil (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Regorafenib (Compound) and Regorafenib may cause a minor interaction that can limit clinical effects when taken with Dapagliflozin